NSE:DIVISLAB

Choice Equity Upgrades Divi's Laboratories to Add from Reduce; Price Target is INR7,375

Jefferies Adjusts Divi's Laboratories' Price Target to INR7,950 from INR8,100, Keeps at Buy

Divi's Laboratories (NSE:DIVISLAB, BOM:532488) has an average rating of hold and mean price target of 6,833.08 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Divi's Laboratories Clocks Gains in Fiscal Q4 Consolidated Profit

Divi's Laboratories' (NSE:DIVISLAB, BOM:532488) consolidated attributable profit increased to 7.51 billion Indian rupees in the fiscal fourth quarter ended March 31, from 6.62 billion rupees a year ago.Earnings per share came in at 28.31 rupees from 24.93 rupees a year earlier, the pharmaceutical company said in a filing to the Indian bourses on Saturday. The EPS was higher than the 26.67 rupees estimated by analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 rose to 28.3 billion rupees from 25.9 billion rupees a year ago.The company's board recommended a final dividend of 30 rupees per equity share of face value 2 rupees each for the financial year 2025-26.